irinotecan has been researched along with imiquimod in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonnard, V; Bonnet, PA; Bressolle, F; Deleuze-Masquefa, C; Gayraud-Paniagua, S; Moarbess, G; Pinguet, F; Vidal, JR | 1 |
| Lang, T; Li, Y; Wu, T; Yan, W; Yin, Q; Yuan, W; Zhu, R; Zou, Y | 1 |
2 other study(ies) available for irinotecan and imiquimod
| Article | Year |
|---|---|
In vitro and in vivo anti-tumoral activities of imidazo[1,2-a]quinoxaline, imidazo[1,5-a]quinoxaline, and pyrazolo[1,5-a]quinoxaline derivatives.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Databases, Factual; Female; Humans; Imidazoles; Mice; Mice, Nude; Molecular Structure; Pyrazoles; Quinoxalines; Xenograft Model Antitumor Assays | 2008 |
Co-delivering irinotecan and imiquimod by pH-responsive micelle amplifies anti-tumor immunity against colorectal cancer.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Colorectal Neoplasms; Hydrogen-Ion Concentration; Imiquimod; Irinotecan; Mice; Micelles | 2023 |